GHK-Cu: The Copper Tripeptide With a Divided Regulatory Status, Decades of Preclinical Evidence, and a PCAC Review Pending Before February 2027

Key takeaways

• GHK-Cu (glycyl-L-histidyl-L-lysine–copper complex) is a naturally occurring tripeptide with a preclinical evidence base stretching back to the early 1970s, but no published human efficacy trials for its injectable or systemic forms.
• In April 2026, the FDA briefly removed GHK-Cu from its Section 503A Category 1 list after nominators withdrew their submissions; one nominator subsequently clarified it intended to withdraw only the injectable route, prompting the FDA to reinstate the non-injectable form to Category 1.
• The injectable form remains in transitional status pending a PCAC review the FDA has committed to scheduling before the end of February 2027.
• GHK-Cu was not among the seven peptides reviewed at the July 2026 PCAC meeting, which focused on BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and emideltide.
• In the UK, GHK-Cu has no MHRA-authorised medicinal product; topical cosmetic use is widespread and regulated under cosmetics law rather than medicines law.

What GHK-Cu is

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. First isolated from human plasma albumin in 1973 by researcher Loren Pickart, the molecule is a naturally occurring component of plasma, saliva and urine. Its plasma concentration declines substantially with age — a pattern that has driven much of the scientific and commercial interest in exogenous supplementation, particularly in dermatology and wound-biology research.

The compound is structurally simple: a tripeptide backbone with a high affinity for divalent copper ions. GHK-Cu stimulates both synthesis and breakdown of collagen and glycosaminoglycans, and modulates the activity of both metalloproteinases and their inhibitors. This dual action on extracellular matrix remodelling distinguishes it from straightforward collagen-stimulating agents and, according to research published in International Journal of Molecular Sciences, suggests it should be used with caution given its capacity to regulate metalloproteinase inhibitors.

Mechanism of action

The primary mechanism proposed in the literature involves copper chelation. Most authors attribute the effects of GHK to its ability to bind copper(II) ions, with that copper complex then modulating a range of downstream signalling pathways. A secondary mechanism, more prominent in research since approximately 2010, involves broad-spectrum gene expression modulation: according to a 2015 review in BioMed Research International, GHK is capable of up- and downregulating at least 4,000 human genes, a claim that warrants contextualisation — this figure derives from computational gene-profiling studies rather than controlled human intervention trials.

Additional proposed mechanisms include suppression of the acute-phase inflammatory response via inhibition of pro-inflammatory cytokines, stimulation of angiogenesis, attraction of immune and endothelial cells to injury sites, and restoration of fibroblast replicative capacity following radiation damage. The molecule attracts immune and endothelial cells to the site of an injury and accelerates wound-healing of the skin, hair follicles, gastrointestinal tract and boney tissue, according to the same review.

State of the preclinical evidence

The preclinical record is substantive, primarily in rodent and rabbit models. In rabbit experimental wounds, GHK alone or in combination with high-dose helium–neon laser improved wound contraction and formation of granular tissue, as well as increasing activity of antioxidant enzymes and stimulating blood vessel growth. Systemic effects have also been demonstrated in animal models: GHK-Cu injected in one area of the body — such as the thigh muscles — improved healing at distant body areas, such as the ears, in rats, mice and pigs, with treated groups showing significantly increased collagen production, angiogenesis and wound closure rates.

A 2025 review published in Medical Science Monitor covering tripeptide wound-healing studies from 2016 to 2025 confirmed that tripeptides such as GHK-Cu can stimulate fibroblast migration, enhance collagen deposition, and support angiogenesis, with antimicrobial and anti-inflammatory properties making them candidates for both acute and chronic wound management.

The critical limitation is translation. The skin and wound-healing effects are supported by laboratory and topical research; controlled human trials examining systemic or injectable GHK-Cu are not represented in the major Western clinical trial registries. In the context of FDA compounding review, the absence of human efficacy data is the same gap that FDA staff cited when recommending against the six July 2026 peptides — a recommendation the PCAC ultimately overrode for all six.

The FDA compounding regulatory journey

GHK-Cu's route through the 503A framework has been notably convoluted compared to the other peptides reviewed in 2026.

Category 1 and the 2026 nomination withdrawal. GHK-Cu had been placed in Category 1 of the FDA's 503A bulk drug substances list — meaning it was under active evaluation but not yet prohibited. According to the FDA's official bulk drug substances document, on 22 April 2026 GHK-Cu was removed from Category 1 because the nominators withdrew their nominations. However, on 5 May 2026, one of those nominators clarified that it had intended to withdraw only its nomination for the injectable route of administration, and wished to retain its nomination for GHK-Cu for non-injectable routes. GHK-Cu (except for injectable routes of administration) was consequently added back to Category 1.

Injectable form in transitional status. GHK-Cu (injectable routes of administration) was simultaneously removed from Category 2 because the original nominations were withdrawn — not because the FDA affirmatively found it safe or eligible for compounding. The legal firm Boesen Snow Law noted that removal from Category 2 means the substance enters a transitional status: no longer prohibited under the Category 2 framework, but not yet formally eligible for compounding.

The February 2027 PCAC commitment. The FDA has confirmed it intends to consult the PCAC on both forms of GHK-Cu before the end of February 2027, though the precise date, time and location of that meeting remain unscheduled as of the time of writing. This means GHK-Cu will face the same advisory committee process that generated six favourable votes from the July 2026 PCAC session — though FDA staff's track record of recommending against inclusion, and the committee's willingness to override those recommendations, introduces genuine uncertainty about the outcome.

What a favourable vote would and would not mean. The July 2026 experience offers a useful template. Even after the PCAC voted 8-6 to recommend BPC-157, KPV and TB-500 for inclusion, those substances remained ineligible for compounding under 503A pending formal FDA rulemaking. As Buchanan Ingersoll & Rooney noted after the July meeting, pharmacies should not interpret a favourable vote as authorisation to begin compounding — formal rulemaking typically takes 8–24 months after a PCAC vote.

Topical versus injectable: a practical distinction for procurement

A feature that distinguishes GHK-Cu from most other peptides in the BSR coverage universe is the pre-existing, legally unrestricted commercial use of its topical form. Synthetic GHK-Cu is widely used in cosmetics as a reparative and anti-ageing ingredient, and this use falls entirely outside the FDA's bulk compounding framework; it is regulated as a cosmetic ingredient rather than a drug. In the UK, topical GHK-Cu products are governed by the UK Cosmetic Products Regulation, not by the MHRA's medicines licensing regime.

Injectable and systemic forms occupy a different legal category entirely. In the UK, no GHK-Cu injectable product holds an MHRA marketing authorisation. Any injectable preparation obtained outside a licensed pharmacy on prescription would fall into the same unregulated supply chain that has drawn enforcement attention from both MHRA and Border Force in recent years.

Research-procurement teams sourcing GHK-Cu for laboratory in vitro or in vivo work should ensure the Certificate of Analysis confirms purity by HPLC (≥98% is standard for research-grade peptides), identity by mass spectrometry, and absence of residual solvents, particularly acetonitrile and trifluoroacetic acid. The copper-chelated form requires additional verification: copper content should be quantified, as inconsistent metal loading will affect any downstream biological assay.

What to watch

• The February 2027 PCAC meeting date: once the FDA schedules and publishes the docket, a public comment period will open; research organisations with relevant data may submit comments.
• FDA's response to the six July 2026 PCAC recommendations: the agency's approach to BPC-157, TB-500 and the others will signal how quickly — and on what evidentiary basis — it is prepared to finalise rulemaking for the broader peptide group, including GHK-Cu.
• Human trial data: any sponsor initiating an IND-covered clinical trial using systemic GHK-Cu would materially alter the regulatory calculus; none appears on ClinicalTrials.gov at present.